Sign inJoin waitlistJoin the waitlist

Keerthi Gogineni

Associate Director, Hematology and Medical Oncology Fellowship Program · Emory University School of Medicine

Credentials: · · · ·

History

Engagement and Inclusivity · Emory University School of Medicine
Present
Emory University School of Medicine
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
Hospital of the University of Pennsylvania
2007–2010
Hospital of the University of Pennsylvania
2004–2007
University of Maryland School of Medicine
2000–2004

Research

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment
Clinical Cancer Research · 2015 · 297 citations
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Review · Breast Cancer · 2016 · Last of 3 authors · 159 citations
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials
Journal of Oncology Practice · 2019 · 69 citations

Mylin Torres
8 papers
Preeti Subhedar
8 papers
EE
Ezekiel Jonathan Emanuel
4 papers
Jane Meisel
4 papers
OD
Olivia D'Angelo
4 papers · 4 as a resident
Uma Krishnamurti
4 papers
Angela DeMichele
2 papers
Anne Gaglioti
2 papers
Derek Chinn
2 papers
JG
Jazib Gohar
2 papers
Jolinta Lin
2 papers
Kevin Kalinsky
2 papers

Clinical trials

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 1
Emory University
2025–2026
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Principal investigator · Terminated · Phase 2
Emory University
2011–2015
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Site PI · Recruiting · Phase 3
BriaCell Therapeutics Corporation
2023–2028
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Site PI · Unknown · Phase 2
Academic and Community Cancer Research United
2020–2025